Affimed NV (LTS:0HL9)
$ 2.22 0.1082 (4.73%) Market Cap: 38.03 Mil Enterprise Value: 25.31 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 26/100

Q4 2021 Affimed NV Earnings Call Transcript

Mar 31, 2022 / 12:30PM GMT
Release Date Price: $43.35 (-3.56%)
Operator

Good day, and thank you for standing by. Welcome to the Affimed 2021 Financial Results and Corporate Update Conference Call. (Operator Instructions) Please be advised today's conference may be recorded. (Operator Instructions)

I'd now like to hand the conference over to Alex Fudukidis, Head of Investor Relations. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, Liz, and thank you all for joining us for our call today. Before we begin, I'd like to remind everyone that we issued the relevant press release earlier today, which can be found on the Investor Relations section of our website.

On the call today, we have the following members of our management team: Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Wolfgang Fischer, our Chief Operating Officer; Denise Mueller, our Chief Business Officer; and Angus Smith, our Chief Financial Officer. The team will be available for the Q&A after the prepared remarks.

Before we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot